However, the use of neoadjuvant therapy with EGFR-TKIs in EGFR-mutant NSCLC remains controversial, especially in pulmonary sarcomatoid carcinoma (PSC). The gene discussed is EGFR; the disease is pancreatic serous cystadenoma.